中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

85 records (took 0.042 seconds)

    COMPOSITIONS AND METHODS OF MODULATING INFLAMMATION
    1.
    发明申请
    COMPOSITIONS AND METHODS OF MODULATING INFLAMMATION 审中-公开

    公开(公告)号：WO2020102108A1

    公开(公告)日：2020-05-22

    申请号：PCT/US2019/060787

    申请日：2019-11-11

    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

    Inventor： KAWAKAMI, Toshiaki ,  KAWAKAMI, Yuko

    IPC: G01N33/564 ,  A61K38/16 ,  A61P37/08 ,  A61P11/06 ,  A61P29/00 ,  C07K16/18

    Abstract: Methods are disclosed for identifying whether a subject is likely to respond to a therapy for treatment of an allergy (e.g., a food allergy or an allergic reaction), hypersensitivity, asthma, inflammatory response or inflammation by detecting the level of an HRF monomer, an HRF dimer, an HRF multimer, or an HRF-reactive Ig molecule in a sample isolated from the subject. Also provided are methods for diagnosing or determining the severity of a condition selected from an allergy (e.g., a food allergy or an allergic reaction), hypersensitivity, asthma, inflammatory response or inflammation/or severity of allergic reaction, or inflammation in a subject. Treatments for allergic conditions are further provided herein, as well as kits for the diagnosis, monitoring and treatment of the conditions.

    METHODS AND COMPOSITIONS USING INTEGRIN-BASED THERAPEUTICS
    6.
    发明申请
    METHODS AND COMPOSITIONS USING INTEGRIN-BASED THERAPEUTICS 审中-公开
    使用基于整合的治疗剂的方法和组合物

    公开(公告)号：WO2017132620A1

    公开(公告)日：2017-08-03

    申请号：PCT/US2017/015506

    申请日：2017-01-27

    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

    Inventor： LEY, Klaus

    IPC: C07K14/78 ,  C07K16/28 ,  C12N15/12 ,  A61K38/17 ,  A61K39/395 ,  A61K31/7088 ,  A61P29/00 ,  A61P37/00

    CPC classification number: A61K31/7088 ,  A61K38/17 ,  C07K14/78 ,  C07K16/2839 ,  C07K2317/30 ,  C07K2317/70

    Abstract: The present invention is directed to modified integrin proteins and methods and compositions using integrin-based therapeutics. In one embodiment, the modified integrins demonstrate increased occurrence or duration of the E-H+ integrin protein conformation. In another embodiment, the compounds of the present invention stabilize E-H+ integrin protein conformation, increasing the occurrence or duration of the E-H+ integrin protein conformation. In another embodiment, the compounds of the present invention inhibit binding of a ligand of an integrin. In yet a further embodiment, the present compounds increase cis binding of the integrin or signaling based thereon. The present compounds decrease the occurrence or duration of trans binding of the integrin or signaling based thereon. The modified integrins and compounds described herein may be used in methods of treating immune modulated diseases or inflammatory diseases or conditions.

    Abstract translation: 本发明涉及修饰的整联蛋白以及使用基于整联蛋白的治疗剂的方法和组合物。 在一个实施方案中，修饰的整联蛋白表现出E-H +整联蛋白构象的发生或持续时间增加。 在另一个实施方案中，本发明化合物稳定了E-H +整联蛋白构象，增加了E-H +整联蛋白构象的发生或持续时间。 在另一个实施方案中，本发明化合物抑制整联蛋白配体的结合。 在又一个实施方案中，本发明化合物增加整联蛋白的顺式结合或基于其的信号传导。 本发明化合物减少整联蛋白的反式结合或基于其的信号传导的出现或持续时间。 本文所述的修饰的整联蛋白和化合物可用于治疗免疫调节的疾病或炎性疾病或病症的方法中。

    METHODS AND COMPOSITIONS FOR MODULATING MONOCYTE POPULATIONS AND RELATED USES THEREOF
    7.
    发明申请
    METHODS AND COMPOSITIONS FOR MODULATING MONOCYTE POPULATIONS AND RELATED USES THEREOF 审中-公开
    调节单胞菌人口的方法和组合物及其相关用途

    公开(公告)号：WO2017044946A1

    公开(公告)日：2017-03-16

    申请号：PCT/US2016/051308

    申请日：2016-09-12

    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

    Inventor： HEDRICK, Catherine ,  THOMAS, Graham

    IPC: C12N5/0786 ,  G01N33/48 ,  G01N33/50

    CPC classification number: C12N5/0645 ,  A01K67/0276 ,  A01K2227/105 ,  A01K2267/0387 ,  C12N15/907 ,  C12Q1/6883

    Abstract: Method and compositions for modulating specific populations of monocytes or macrophages are disclosed. Methods include, in certain embodiments, modulating expression or activity of Nr4a1 (Nur77). Compositions disclosed herein include agonistic and antagonistic agents that modulate expression or activity of Nur77, and uses thereof. In various embodiments, methods of treating certain disorders and diseases related to aberrant monocyte or macrophage development are provided. In further various embodiments, methods of identifying agents that modulate specific populations of monocytes or macrophages, and agents that modulate Nur77 activity and/or expression are provided.

    Abstract translation: 公开了调节单核细胞或巨噬细胞特异性群体的方法和组合物。 在某些实施方案中，方法包括调节Nr4a1（Nur77）的表达或活性。 本文公开的组合物包括调节Nur77的表达或活性的激动剂和拮抗剂及其用途。 在各种实施方案中，提供了治疗与异常单核细胞或巨噬细胞发育相关的某些疾病和疾病的方法。 在进一步的各种实施方案中，提供了鉴定调节单核细胞或巨噬细胞的特定群体的试剂和调节Nur77活性和/或表达的试剂的方法。

    CXCL13 AS AN INDICATOR OF GERMINAL CENTER ACTIVITY AND IMMUNE RESPONSE
    9.
    发明申请
    CXCL13 AS AN INDICATOR OF GERMINAL CENTER ACTIVITY AND IMMUNE RESPONSE 审中-公开
    CXCL13作为终端中心活动指标和免疫应答

    公开(公告)号：WO2016154553A1

    公开(公告)日：2016-09-29

    申请号：PCT/US2016/024255

    申请日：2016-03-25

    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY

    Inventor： CROTTY, Shane

    IPC: G01N33/50 ,  G01N33/68 ,  G01N33/48

    CPC classification number: G01N33/6863 ,  G01N2333/522 ,  G01N2800/102 ,  G01N2800/104 ,  G01N2800/24

    Abstract: Presented herein are methods of detecting and/or monitoring germinal center activity in a subject according to an amount of CXCL13 in the blood of a subject. Also presented herein are methods of determine the efficacy of a vaccine or antigen at inducing an immune response. Methods are also presented for monitoring, screening, and/or diagnosing an autoimmune disorder or immune-suppression in a subject and for monitoring or adjusting a treatment.

    Abstract translation: 本文提出的是根据受试者血液中CXCL13的量来检测和/或监测受试者中的生发中心活动的方法。 本文还介绍了确定疫苗或抗原诱导免疫应答的功效的方法。 还提供了用于监测，筛选和/或诊断受试者中的自身免疫疾病或免疫抑制以及用于监测或调整治疗的方法。

    REDUCING DIABETES IN PATIENTS RECEIVING HMG-COA REDUCTASE INHIBITORS (STATINS)
    10.
    发明申请
    REDUCING DIABETES IN PATIENTS RECEIVING HMG-COA REDUCTASE INHIBITORS (STATINS) 审中-公开
    减少接受HMG-COA还原抑制剂（STATINS）的患者的糖尿病

    公开(公告)号：WO2014153424A1

    公开(公告)日：2014-09-25

    申请号：PCT/US2014/031257

    申请日：2014-03-19

    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY ,  LINDEN, Joel

    Inventor： LINDEN, Joel

    IPC: A61K31/52

    CPC classification number: A61K31/522 ,  A61K31/506 ,  A61K2300/00

    Abstract: The invention provides compositions, methods and uses for reducing insulin resistance or risk of diabetes in a subject taking a statin. The invention also provides compositions, methods and uses for reducing or decreasing increases in blood glucose caused by a statin in a subject taking a statin. The invention further provides compositions, methods and uses for reducing insulin resistance or risk of diabetes in a subject taking statins, and for treating diabetes in a subject taking statins. The invention moreover provides compositions, including an adenosine receptor antagonist, and/or an A2B receptor antagonist, and/or a CD73 antagonist and a statin.

    Abstract translation: 本发明提供了在服用他汀类药物的受试者中降低胰岛素抵抗或糖尿病风险的组合物，方法和用途。 本发明还提供了在服用他汀类药物的受试者中降低或降低由他汀类药物引起的血糖升高的组合物，方法和用途。 本发明还提供了在服用他汀类药物的患者中降低胰岛素抵抗或糖尿病风险的组合物，方法和用途，并且用于治疗服用他汀类药物的受试者的糖尿病。 本发明还提供了包括腺苷受体拮抗剂和/或A2B受体拮抗剂和/或CD73拮抗剂和他汀类的组合物。

Patent Agency Ranking